Multiple law firms filed a securities fraud class action lawsuit against GeneDx Holdings Corp. The legal action represents investors who purchased shares between April 16, 2025, and May 4, 2026. The lawsuit alleges the company issued misleading statements about the Fabric Genomics acquisition and its projected financial benefits.
GeneDx reported its first-quarter 2026 results on May 4, 2026. The announcement revealed a significant decline in adjusted gross margin. The company also lowered its future earnings projections.
The financial update included a $31.3 million impairment loss related to the Fabric Genomics deal. GeneDx shares dropped more than 49% following the news. Investors must file for lead plaintiff status by August 3, 2026.